加载中
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
常规交易时段
US$54.0267
−US$1.2433 · -2.25%
盘中时间采用ET。市场数据可能有所延迟。
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
日内区间
当前US$54.0267
52周区间
当前US$54.0267
盘中时间采用ET。市场数据可能有所延迟。
GoAI 评分
买入
估值
87
深度低估
情绪
73
看涨
风险
41
风险偏高
动量
74
动能增强
完整 GoAI 研究
继续查看更深入的依据、催化因素和风险。
Based in New York City and established in 1993, TG Therapeutics, Inc. is a biopharmaceutical company that has advanced to the commercial stage. Its core mission revolves around the acquisition, advancement, and marketing of novel therapeutic solutions. The company's focus areas specifically include B-cell related cancers (malignancies) and various autoimmune disorders. Among its significant investigational therapeutic candidates is Ublituximab, a distinctive glycoengineered monoclonal antibody currently undergoing evaluation. It targets B-cell non-Hodgkin lymphoma, chronic lymphocytic leukemia (CLL), and the relapsing forms of multiple sclerosis. Another compound in its pipeline is Umbralisib, an orally administered inhibitor designed to block PI3K-delta and CK1-epsilon enzymes. This treatment is being investigated for its effectiveness against CLL, marginal zone lymphoma, and follicular lymphoma. TG Therapeutics is also developing Cosibelimab, an IgG1 human monoclonal antibody that functions by binding to programmed death-ligand 1 (PD-L1) and subsequently preventing its interaction with PD-1 and B7.1 receptors. Furthermore, the company is advancing TG-1701, an oral, covalently-bound Bruton's tyrosine kinase (BTK) inhibitor, notably more selective for BTK compared to ibrutinib in laboratory screenings. Completing this clinical-stage portfolio is TG-1801, a bispecific antibody engineered to simultaneously target CD47 and CD19. Beyond its clinical-stage assets, the company possesses various licensed preclinical programs, including those addressing BET, interleukin-1 receptor associated kinase-4, and GITR. To enhance its research and development capabilities, TG Therapeutics has forged collaboration agreements with entities such as Checkpoint Therapeutics, Inc., Jiangsu Hengrui Medicine Co., Novimmune SA, Ligand Pharmaceuticals Incorporated, and Jubilant Biosys. The company also maintains strategic alliances with partners including LFB Biotechnologies S.A.S, GTC Biotherapeutics, LFB/GTC LLC, Ildong Pharmaceutical Co. Ltd., and Rhizen Pharmaceuticals, S A.
日内区间
当前US$54.0267
52周区间
当前US$54.0267
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 6.16亿 USD | 3.29亿 USD | 2.34亿 USD | 278.5万 USD | 668.9万 USD |
| 销货成本 | 1.01亿 USD | 3848.6万 USD | 1413.1万 USD | 26.5万 USD | 79万 USD |
| 毛利 | 5.16亿 USD | 2.91亿 USD | 2.2亿 USD | 252万 USD | 589.9万 USD |
| 研究与开发 | 1.6亿 USD | 9429.1万 USD | 7619.2万 USD | 1.25亿 USD | 2.23亿 USD |
| 销售、一般及管理费用 | 2.32亿 USD | 1.54亿 USD | 1.23亿 USD | 9548.4万 USD | 1.28亿 USD |
| 营业费用 | 3.92亿 USD | 2.49亿 USD | 1.99亿 USD | 2.21亿 USD | 3.51亿 USD |
| 利息支出 | 2672.7万 USD | 2402.8万 USD | 1261.5万 USD | 1019.1万 USD | 563.8万 USD |
| 折旧和摊销 | 24.4万 USD | 28万 USD | 42.3万 USD | 51.5万 USD | 49.4万 USD |
| 营业利润 | 1.23亿 USD | 4192.9万 USD | 2063.3万 USD | −2.18亿 USD | −3.45亿 USD |
| 净利润 | 4.47亿 USD | 2338.3万 USD | 1267.2万 USD | −2.24亿 USD | −3.48亿 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$80.50
上涨空间 49.00%| 行动 | 生效日期 | 详情 | 记录日期 | 付款日期 |
|---|---|---|---|---|
股票拆分 | 2012年4月30日 | 4:225 | — | — |
股票拆分 | 2011年7月14日 | 1:50 | — | — |
股票拆分 | 2003年9月29日 | 1:5 | — | — |
已生效 2012年4月30日
4:225
已生效 2011年7月14日
1:50
已生效 2003年9月29日
1:5
报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI2.38亿0.01%2.3万亿 USD0.03%US$381.49-0.02%
iShares Russell 2000 ETFIWM2.06亿0.27%787.4亿 USD0.19%US$277.1-0.29%
Vanguard Morningstar Small-Cap ETFVB1.72亿0.09%1853亿 USD0.03%US$288.47+0.11%
State Street SPDR S&P Biotech ETFXBI1.56亿1.51%103.03亿 USD0.35%US$147.41-2.64%
Vanguard Morningstar Small-Cap Growth ETFVBK9880.16万0.22%447亿 USD0.05%US$339.13-0.51%
First Trust NYSE Arca Biotechnology Index FundFBT8840.77万3.05%28.91亿 USD0.55%US$259.92-1.51%
Vanguard Extended Market ETFVXF8315.77万0.09%954亿 USD0.05%US$232.69-0.36%
iShares Russell 2000 Growth ETFIWO7433.17万0.54%139.17亿 USD0.24%US$351.59-0.60%Vanguard Morningstar Total Stock Market ETFVTIiShares Russell 2000 ETFIWMVanguard Morningstar Small-Cap ETFVBState Street SPDR S&P Biotech ETFXBIVanguard Morningstar Small-Cap Growth ETFVBKFirst Trust NYSE Arca Biotechnology Index FundFBTVanguard Extended Market ETFVXFiShares Russell 2000 Growth ETFIWOAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
